Cardiorenal protection during chronic renin–angiotensin–aldosterone system suppression: evidences and caveats
Blocking the renin–angiotensin–aldosterone system (RAAS) has widely shown to be good for the protection of both cardiovascular and renal systems. A large number of trials have demonstrated clear benefits of using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs...
Gespeichert in:
Veröffentlicht in: | European heart journal. Cardiovascular pharmacotherapy 2015-04, Vol.1 (2), p.126-131 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 131 |
---|---|
container_issue | 2 |
container_start_page | 126 |
container_title | European heart journal. Cardiovascular pharmacotherapy |
container_volume | 1 |
creator | Ruiz-Hurtado, Gema Ruilope, Luis Miguel |
description | Blocking the renin–angiotensin–aldosterone system (RAAS) has widely shown to be good for the protection of both cardiovascular and renal systems. A large number of trials have demonstrated clear benefits of using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) to treat patients with established cardiovascular and renal disease during the last decades. Even more, simultaneous protection of cardiovascular and renal system with RAAS blockade has also been shown. However, some caveats of this therapy as the effectiveness lack in long-term, hyperkalaemia risk in patients with chronic kidney disease or aldosterone and albuminuria breakthrough limit their use, lead that new therapeutic strategies are needed for the RAAS blockade. At this time, new horizons are opened to manage the RAAS blockade in the cardiorenal disease through using the positive combination of an ACEi or an ARB plus and aldosterone antagonist, renin inhibitors, or other forms of blockade using new members as LCZ696. |
doi_str_mv | 10.1093/ehjcvp/pvu023 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1812880542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjcvp/pvu023</oup_id><sourcerecordid>1812880542</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-14591c5d0493d5f6afafbca72fe0dbbe642dd1a98259160182354f98fbaf08313</originalsourceid><addsrcrecordid>eNqFkL1OxDAQhC0E4tBBSYtc0gT8E-ccOnTiT0KigTpy7DX4lDjBTiLR8Q68IU-CUQ4oqXZW-2lWMwgdU3JGScnP4WWjp_68n0bC-A46YESIrJC52P3VfLVARzFuCCG0kAWTfB8t2EpwXkp2gF7XKhjXBfCqwX3oBtCD6zw2Y3D-GeuX0Hmncbo7__n-ofyzS4yP89aYLg6QEMDxLakWx7HvA8SYPC4wTM6A1xCx8gZrNYEa4iHas6qJcLSdS_R0ffW4vs3uH27u1pf3mc45HTKai5JqYUheciNsoayytVYrZoGYuoYiZ8ZQlUIkriBUMi5yW0pbK0skp3yJTmfflOp1hDhUrYsamkZ56MZYUUmZlETkLKHZjOrQxRjAVn1wrQpvFSXVd9HVXHQ1F534k631WLdgfumfWv9-d2P_j9cXHT6Opw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1812880542</pqid></control><display><type>article</type><title>Cardiorenal protection during chronic renin–angiotensin–aldosterone system suppression: evidences and caveats</title><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Ruiz-Hurtado, Gema ; Ruilope, Luis Miguel</creator><creatorcontrib>Ruiz-Hurtado, Gema ; Ruilope, Luis Miguel</creatorcontrib><description>Blocking the renin–angiotensin–aldosterone system (RAAS) has widely shown to be good for the protection of both cardiovascular and renal systems. A large number of trials have demonstrated clear benefits of using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) to treat patients with established cardiovascular and renal disease during the last decades. Even more, simultaneous protection of cardiovascular and renal system with RAAS blockade has also been shown. However, some caveats of this therapy as the effectiveness lack in long-term, hyperkalaemia risk in patients with chronic kidney disease or aldosterone and albuminuria breakthrough limit their use, lead that new therapeutic strategies are needed for the RAAS blockade. At this time, new horizons are opened to manage the RAAS blockade in the cardiorenal disease through using the positive combination of an ACEi or an ARB plus and aldosterone antagonist, renin inhibitors, or other forms of blockade using new members as LCZ696.</description><identifier>ISSN: 2055-6837</identifier><identifier>EISSN: 2055-6845</identifier><identifier>DOI: 10.1093/ehjcvp/pvu023</identifier><identifier>PMID: 27533982</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><ispartof>European heart journal. Cardiovascular pharmacotherapy, 2015-04, Vol.1 (2), p.126-131</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com 2015</rights><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-14591c5d0493d5f6afafbca72fe0dbbe642dd1a98259160182354f98fbaf08313</citedby><cites>FETCH-LOGICAL-c431t-14591c5d0493d5f6afafbca72fe0dbbe642dd1a98259160182354f98fbaf08313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27533982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruiz-Hurtado, Gema</creatorcontrib><creatorcontrib>Ruilope, Luis Miguel</creatorcontrib><title>Cardiorenal protection during chronic renin–angiotensin–aldosterone system suppression: evidences and caveats</title><title>European heart journal. Cardiovascular pharmacotherapy</title><addtitle>Eur Heart J Cardiovasc Pharmacother</addtitle><description>Blocking the renin–angiotensin–aldosterone system (RAAS) has widely shown to be good for the protection of both cardiovascular and renal systems. A large number of trials have demonstrated clear benefits of using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) to treat patients with established cardiovascular and renal disease during the last decades. Even more, simultaneous protection of cardiovascular and renal system with RAAS blockade has also been shown. However, some caveats of this therapy as the effectiveness lack in long-term, hyperkalaemia risk in patients with chronic kidney disease or aldosterone and albuminuria breakthrough limit their use, lead that new therapeutic strategies are needed for the RAAS blockade. At this time, new horizons are opened to manage the RAAS blockade in the cardiorenal disease through using the positive combination of an ACEi or an ARB plus and aldosterone antagonist, renin inhibitors, or other forms of blockade using new members as LCZ696.</description><issn>2055-6837</issn><issn>2055-6845</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFkL1OxDAQhC0E4tBBSYtc0gT8E-ccOnTiT0KigTpy7DX4lDjBTiLR8Q68IU-CUQ4oqXZW-2lWMwgdU3JGScnP4WWjp_68n0bC-A46YESIrJC52P3VfLVARzFuCCG0kAWTfB8t2EpwXkp2gF7XKhjXBfCqwX3oBtCD6zw2Y3D-GeuX0Hmncbo7__n-ofyzS4yP89aYLg6QEMDxLakWx7HvA8SYPC4wTM6A1xCx8gZrNYEa4iHas6qJcLSdS_R0ffW4vs3uH27u1pf3mc45HTKai5JqYUheciNsoayytVYrZoGYuoYiZ8ZQlUIkriBUMi5yW0pbK0skp3yJTmfflOp1hDhUrYsamkZ56MZYUUmZlETkLKHZjOrQxRjAVn1wrQpvFSXVd9HVXHQ1F534k631WLdgfumfWv9-d2P_j9cXHT6Opw</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Ruiz-Hurtado, Gema</creator><creator>Ruilope, Luis Miguel</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Cardiorenal protection during chronic renin–angiotensin–aldosterone system suppression: evidences and caveats</title><author>Ruiz-Hurtado, Gema ; Ruilope, Luis Miguel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-14591c5d0493d5f6afafbca72fe0dbbe642dd1a98259160182354f98fbaf08313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruiz-Hurtado, Gema</creatorcontrib><creatorcontrib>Ruilope, Luis Miguel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal. Cardiovascular pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruiz-Hurtado, Gema</au><au>Ruilope, Luis Miguel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiorenal protection during chronic renin–angiotensin–aldosterone system suppression: evidences and caveats</atitle><jtitle>European heart journal. Cardiovascular pharmacotherapy</jtitle><addtitle>Eur Heart J Cardiovasc Pharmacother</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>1</volume><issue>2</issue><spage>126</spage><epage>131</epage><pages>126-131</pages><issn>2055-6837</issn><eissn>2055-6845</eissn><abstract>Blocking the renin–angiotensin–aldosterone system (RAAS) has widely shown to be good for the protection of both cardiovascular and renal systems. A large number of trials have demonstrated clear benefits of using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) to treat patients with established cardiovascular and renal disease during the last decades. Even more, simultaneous protection of cardiovascular and renal system with RAAS blockade has also been shown. However, some caveats of this therapy as the effectiveness lack in long-term, hyperkalaemia risk in patients with chronic kidney disease or aldosterone and albuminuria breakthrough limit their use, lead that new therapeutic strategies are needed for the RAAS blockade. At this time, new horizons are opened to manage the RAAS blockade in the cardiorenal disease through using the positive combination of an ACEi or an ARB plus and aldosterone antagonist, renin inhibitors, or other forms of blockade using new members as LCZ696.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>27533982</pmid><doi>10.1093/ehjcvp/pvu023</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2055-6837 |
ispartof | European heart journal. Cardiovascular pharmacotherapy, 2015-04, Vol.1 (2), p.126-131 |
issn | 2055-6837 2055-6845 |
language | eng |
recordid | cdi_proquest_miscellaneous_1812880542 |
source | PubMed Central; Alma/SFX Local Collection |
title | Cardiorenal protection during chronic renin–angiotensin–aldosterone system suppression: evidences and caveats |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T15%3A31%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiorenal%20protection%20during%20chronic%20renin%E2%80%93angiotensin%E2%80%93aldosterone%20system%20suppression:%20evidences%20and%20caveats&rft.jtitle=European%20heart%20journal.%20Cardiovascular%20pharmacotherapy&rft.au=Ruiz-Hurtado,%20Gema&rft.date=2015-04-01&rft.volume=1&rft.issue=2&rft.spage=126&rft.epage=131&rft.pages=126-131&rft.issn=2055-6837&rft.eissn=2055-6845&rft_id=info:doi/10.1093/ehjcvp/pvu023&rft_dat=%3Cproquest_cross%3E1812880542%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1812880542&rft_id=info:pmid/27533982&rft_oup_id=10.1093/ehjcvp/pvu023&rfr_iscdi=true |